The CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial has spurred debate over subgroup analysis interpretation and prompted renewed consideration of the long-term role of dual aspirin and clopidogrel therapy (DAPT) in patients with established vascular disease.
- Platelet Aggregation Inhibitors
- Randomized Controlled Trials as Topic
- Retrospective Studies
- Time Factors
- Vascular Diseases